Progestogen only contraception in women with congenital heart disease

Background: There is little information of progestogen-only contraceptives in patients with congenital heart disease (CHD) on the long-term. Objective: To evaluate the use of contraception in patients with CHD. We studied both short-acting reversible contraceptives (SARCs), oral progestin-only pills...

ver descrição completa

Detalhes bibliográficos
Autores: Baró-Mariné, Francesc, Pijuan-Domènech, Antonia|||0000-0003-0893-3692, Goya, M|||0000-0003-4001-2017, Suárez-Edo, Elena|||0009-0003-4805-3849, Miranda, Berta|||0000-0003-1617-1050, Dos Subira, Laura|||0000-0001-5821-4501, Pancorbo, Maria Luisa|||0000-0002-2925-9353, Ferreira-Gonzalez, Ignacio|||0000-0002-1208-5561, Carreras Moratonas, Elena|||0000-0003-3471-7248
Formato: artículo
Fecha de publicación:2024
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:310396
Acesso em linha:https://ddd.uab.cat/record/310396
https://dx.doi.org/urn:doi:10.1080/01443615.2024.2320296
Access Level:acceso abierto
Palavra-chave:Congenital heart disease
LARCs methods (long-acting reversible contraceptive)
SARCs methods (short-acting reversible contraceptive)
Progesterone only contraception
Descrição
Resumo:Background: There is little information of progestogen-only contraceptives in patients with congenital heart disease (CHD) on the long-term. Objective: To evaluate the use of contraception in patients with CHD. We studied both short-acting reversible contraceptives (SARCs), oral progestin-only pills (POPs) and long-acting reversible contraceptives (LARCs): intrauterine devices (IUD-IPs) and subdermal implants both impregnated with progestogens (SI-IPs). Study design: Retrospective study of all women attending the preconception clinic. Contraceptive methods were classified in three TIERs of effectiveness before and after consultation. ESC classification regarding pregnancy risk, WHOMEC classification for combined oral contraceptive safety was collected. Results: Six hundred and fifty-three patients. A significant proportion of them switched from TIER 3 to TIER 2 or 1 (p < .001) after consultation. One hundred and ninety-nine patients used POPs, 53 underwent IUD-IPs implantation and 36 SI-IPs, mean duration was 58 ± 8, 59 ± 8 and 53 ± 38 months, respectively. Conclusions: Because of their safety and efficacy, IUD-IPs and SI-IPs should be considered as first-line contraception in patients with CHD.

Registos relacionados